A letter to the editor clarifies the renal dosing of apixaban (Eliquis) for venous thromboembolism, based on the AMPLIFY trial and the manufacturer's recommendation. The authors recommend no dose adjustment for apixaban in patients with impaired renal function, but careful monitoring.
by LLK Leung Cited by 42- Dosing, monitoring, risks (apixaban) Edoxaban - Overview (edoxaban) renal insufficiency (adults) - Anticoagulant dose adjustment in
The total and renal elimination of apixaban were characterized in two IV studies including 50 healthy subjects administered a single IV dose of apixaban (0.5 5 mg) [23, 24]. In these studies, apixaban renal clearance was 27% of total clearance on average.
Dosing. Arzneimitteldosierung bei Niereninsuffizienz Meta-analysis on risk of bleeding with apixaban in patients with renal impairment.
Composite rate of incorrect doses of apixaban safety of apixaban in subjects with end-stage renal disease on Rates of incorrect apixaban dosing are high
ELIQUIS (apixaban) DOSING SUMMARY. ▽ After 7 days, transition Renal impairment: Anti-FXa activity adjusted for exposure to apixaban was similar across.
Apixaban is less dependent on renal excretion, and based on pharmacokinetic data, current labeling recommends standard-dose apixaban in dialysis patients. Until now, however, there have been no data on clinical outcomes.
(Dabigatran. 110 mg dose non-inferior to warfarin.) Severe renal impairment. (CrCl 30 mL/min). Apixaban. Warfarin. Dabigatran contraindicated. Apixaban
Apixaban is less dependent on renal excretion, and based on dose apixaban in dialysis patients. Until now, however, there have
Comments